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B 4.2
Pharmacotherapy for Symptoms of Intermittent
Claudication
B 4.2.1
lntroductlon
Patients with intermittent claudication mostly receive
drug treatment for coexisting disease (eg, hyperten-
sion), risk factor modification (eg, hyperlipidaemia),
and as prophylaxis against thrombotic events associ-
ated with atherosclerosis (eg, antiplatelet drugs). No
pharmacological agent has proved efficacious enough
in providing significant reduction or elimination of
symptoms of claudication to gain Widespread accept-
ance and use for improving walking. However, a
number of types of drugs have been promoted for this
indication, with varying evidential support, and these
will be considered in this section. These drugs are fre-
quently grouped together under the heading "vasoac-
tive agents," partly because of their multiplicity of
potential mechanisms of action. Some of the drugs
have been distinguished as "rheologic agents," but
for others such as prostanoids, the mode of action is
still not well delineated. These drugs should not
replace exercise programs and other lifestyle adjust-
ments described in B 4.1.2, Basic Treatment (p 568).
However, they have a place as adjunctive treatment
where invasive therapy is not indicated, in those who
cannot or will not follow exercise therapy or in those
who have not sufficiently benefited from it (see D
4.13.5, Adjuvant Therapy, p 5211). Table 16 and Figure
20 show results of randomised, placebo-controlled,
double-blind trials of pharmacotherapy in Ie.
B 4.2.2
Established Drugs With Proven but Small Benefit in
Improving Claudication
Pell toxiJtJllille
Pentoxifylline improves red cell deformability, lowers
fibrinogen levels, decreases platelet aggregation, and
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has been shown to increase walking distance in
patients with PAD. In early controlled trials, the drug
produced a 22% improvement over placebo in ICD
and a 12% improvement in the ACD.I However, these
percent improvements were expressed as the mean
difference between week 2 and week 24. The actual
improvement over placebo from entry to 6 months in
ACD was 18%, but this difference was not statistically
significant. A more recent study confirmed these
results, with a 21% improvement over placebo (p =
0.09).2The study showed that a subgroup of patients
with symptoms for longer than a year and an ABPI <
0.80 responded better to the drug. Importantly,
patient-based questionnaires to assess efficacy have
not been employed in the clinical trials of pentoxi-
fylline, so the actual clinical benefit of the drug has not
been fully defined.
Naflidrofllryl
Naftidrofuryl has been available for treating IC for over
20 years. It is a 5HT antagonist and may improve aero-
bic metabolism in oxygen-depleted tissues and possibly
reduce erythrocyte and platelet aggregation.' In four
placebo-controlled studies, Naftidrofuryl was more
effective than placebo in improving walking dis-
tance,4.5.6.7 and a further study showed no significant
difference,"
Bltjlomedil
Buflomedil has an alpha-1 and -2 adrenolytic effect. It
has been shown to decrease vasoconstriction. It has
also been shown to have some effect on platelets, red
cell deformability, and a weak calcium antagonist
effect. Buflomedil has been available for the treatment
of IC in some countries for over 10 years. Two rela-
tively small studies, conducted more than 10 years
ago, showed a significantly greater improvement in
absolute walking distance with Buflomedil compared
with placebo.vw
Cilostazol
Cilostazol is a phosphodiesterase III inhibitor with
vasodilator and antiplatelet activity," The first pub-
lished double-blind trial showed a 47% increase in
ACD in the treatment group compared to 13%
increase in the placebo group (Table 16).12 This trial
also showed that all subgroups of patients (age, smok-
ing status, gender, race, and diabetes) responded
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Table 16. Randomised, placebo-controlled, double-blind trials of phannacotherapy in intennittent claudication
Duration ~ACD (%)
N Dose (weeks) Placebo Drug p value WIQ/SF-36' Comments
Cilostazol:
Money et al, 199812 239 200mg/d 16 13 47 <0.001 Yes
Dawson et al, 199813 81 200mg/d 12 10 63 <0.01 Yes
Pentoxijulline:
1.2 g/dLindgarde et al, 19892 150 24 29 50 0.09 No
(subset) 109 1.2 g/d 24 30 63 <0.05 No
Porter et al, 19821 128 1.2 g/d 24 38 56 0.19 No
Naftidrofllryl:
Moody et al,? 1984 180 633 mg 24 t25 t31 0.045 Yes ICD data
only
Kriessmann & Neiss," 1988 136 633mg 12 35 78 <0.05 No ICDdata
only
Adhoute et aI,S 1990 118 600mg 24 46 93 <0.05 No ICDdata
only
Triibestein et al,81994 104 600mg 12 40 55 NS No
Adhoute et aV 1986 94 633mg 24 28 60 <0.001 Yes
BlIjIomcdil:
Triibestein 19849 113 600mg 14 43 97 <0.01 No
Diamantopoulos et al,1O 1989 34 600mg 24 9 68 0.011 No All diabetic
patients
Ticlopidiue:
Balsano et alp 1989 151 500mg/d 21 mo 38 71 <0.01 No
Verapamil:
Bagger et al,2J 1997 44 120-480 mg 2 -2 49 <0.001 No Cross-
over trial
Dextran:
Ernst et alp 1990 20 500mL 6 0 39 <0.001 No Cross-over
trial
Hexopal:
Kiff,31 1988 80 4 g/d 12 87 50 NS Yes
Cinnarizinc:
Barber et aJ,29 1980 45 225mg 16 11 142 No ICDdata
only
Donald.>' 1979 40 225mg 12 34 113 NS No ICDdata
only; cross-
over trial
Staessen." 1977 26 200mg 16 30:j: 75:j: <0.05 Yes Phcnob-
arbitone-
placebo
Propionul-l-carnitinc:
Brevetti et aJ,32 1995 245 1-3 g/d 24 46 73 <0.05 No
Brevetti et a1,J3 1996 485 2g/d 52 50 64 <0.05 No
Bcraprost:
Lievre et al,J.l 1996 83 120 g/d 12 41 91 NS No Optimal
dose group
PGEI:
Diehm et a1,351997 213 60 mg/d 8 60 101 <0.05 No
Belch et al,> 1997 80 3 doses 8 -14 53 <0.01 Yes
NOTE. ~ACD=% change in absolute walking distance; NS, not significant.
'Functional assessment as defined by WIQ and SF-36.
tPercentage of patients with ;<50% increase in baseline ACD.
:j:Percentage of patients with 100% or greater increase in baseline ACD.
equally well to cilostazol. Quality of life was assessed
in this trial using the medical outcomes study SF-36
questionnaire. This showed that patients on cilostazol
had significant improvement in their physical func-
tioning relative to those on placebo. They reported
improved physical performance in the community set-
ting. Mental health scores were unaffected by treat-
ment. Side effects included headache, diarrhoea, and
dizziness. Further randomised multicentre studies
have been publlshed'v'! and also show consistent
improvements in ICD and ACD in the cilostazol group
as compared with placebo. Subjective functional
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• Thickness of bars Indicates total number of patients In trial
• From Table 16. Studies with fewer than 50 patients are omitted.
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Fig. 20. Randorniscd placebo-controlled, double-blind trials of pharmacotherapy in intermittent claudication.
assessment was not well asse ssed but did suggest that
there was drug effect, as noted by both patients and
physlcians.n
B 4.2.3
Drugs With Minimal or No Benefit in Improving
Claudication
Ant iplntclet drugs
As discussed previously, the use of aspirin and other
antlplatelet agents are important in the long-term
treatment of peripheral atherosclerosis assuming a
significant degree of multisystem involvement, main-
ly to reduce the overall incidence of cardiovascular
events (see Recommendation 28, p 71). However, no
studies have shown a benefit of aspirin in the treat-
ment of claudication per se, although there is one
study that presented suggestive evidence that aspirin
slowed progression of atherosclerosis assessed by seri-
al angiography.w In contrast, ticlopidine, a potent
inhibitor of platelet aggregation that also has
hemorheologic effects, was shown in two randomised,
placebo-controlled trials to improve claudication
symptoms and exercise perforrnancevw (Table 16).
However, only one of these studies, by Balsano et al,
had evaluable data. In that trial, treadmill testing was
performed on the flat, and therefore, the clinical bene-
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fits of the drug may have been overestimated because
of the very low treadmill workload.
Vasodilators
Arteriolar vasodilators were the first class of agents
used to treat claudication. Examples include drugs
that inhibit the sympathetic nervous system (alpha
blockers), direct-acting vasodilators (papaverine),
beta- agonists (nylidrin), calcium channel blockers
(nifedipine), and angiotensin-converting enzyme
inhibitors. These drugs have not been shown to have
clinical efficacy in randomised, controlled trials. 19.2o,21
There are several theoretical reasons why vasodilators
may not be effective. Most importantly, in the exercis-
ing claudicant, vessels in ischaemic areas are already
maximally dilated, so vasodilator drugs will only cre-
ate a steal phenomena by dilating vessels in normally
perfused tissues (primarily proximal muscles), thus
shifting the distribution of blood flow away from
muscles supplied by obstructed arteries.
Keianserin
Ketanserin is a selective serotonin (52) antagonist that
lowers blood viscosity and also has vasodilator and
antiplatelet properties. Controlled trials of this drug
have shown it not to be effective in treating claudica-
tionP
Veraptnnil
One study has looked at the possibility that the calci-
um antagonist veraparnil may have a clinical benefit
in patients with intermittent claudication. Although
treatment was only for 2 weeks and the study design
could be criticised, the ACD was statistically signifi-
cantly greater in the treated than in the placebo
group.23
lsooolaetnic haentodilution
Isovolaemic haemodilution has been advocated for
the treatment of IC even in the absence of poly-
cythaemia. No doubt, haernodilution lowers the vis-
cosity of whole blood, but it is still uncertain whether
the increase in blood flow compensates for the
decrease in oxygen-carrying capacity of the blood.
One double-blind, placebo controlled trial of dextran
haernodilution showed efficacy in selected patients."
Am inoplrfllinc
Aminophylline inhibits adenosine receptors and thus
may blunt the vasodilatation response during exer-
cise. This effect would theoretically limit the steal of
blood away from ischaemic skeletal muscle. One
study has shown that intravenous aminophylline
improves treadmill exercise performance in patients
with claudlcatlon.>
Vitamin E
Five randomised controlled trials have been published
since 1953 regarding the use of vitamin E and the treat-
ment of claudication. Although some results are
encouraging, there is insufficient evidence to recom-
mend the routine use of vitamin E in patients with IC.26
Defibrotide
Defibrotide is a polydeoxyribonucleotide drug with
anti thrombotic and haemorrheological properties . A
meta-analysis was performed in 1994 on 10 placebo-
controlled trials of defibrotide in patients with PAD
stage II (406 patients on defibrotide, 337 patients on
placebo). The drug was used at a dose of 400 to 800 mg
daily, the treatment ranging from 60 to 180 days. There
was a net gain in absolute walking distance over place-
bo of 73 m (95% confidence interval; range, 35-111 m)."
Othervasoactive drugs
Other drugs that have been promoted include cinnar-
izine,28,29,30 cyclandelate, nicotinic acid derivatives,"
Ginkgo biloba, and Isosuprine. However, there is no con-
sistent scientific evidence of efficacy for any of these.
Recommendation 30: Pharmacotherapy for
symptoms of intermittent claudication
Although some controlled clinical trials with pen-
toxifylline, naftidrofuryl, buflomedil, and recently
cilostozol, have shown statistically significant
improvement in walking distance, the average ben-
efit was small. Greater benefit, observed in a
minority of patients, may warrant a short course of
therapy with continued use of such agents if suffi-
cient benefit is observed. Recent clinical trials have
shown a greater benefit of cilostazol for both walk-
ing distance and quality of life, which may warrant
more Widespread use. However, currently there are
insufficient data to recommend the routine use of
pharmacotherapy in all patients with claudication.
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B 4.2.4
Incompletely Studied Drugs With Potential Benefit in
Improving Claudication
Carnitine
Patients with PAD not only have a limited arterial
blood flow but also develop metabolic abnormalities
in their skeletal muscle. An example of this is changes
in carnitine metabolism. Patients with PAD have been
shown to accumulate acylcarnitines (intermediates of
oxidative metabolism) in their skeletal muscle." This
abnormal accumulation of acylcarnitines is directly
correlated with impaired exercise performance. It has
thus been hypothesised that supplementation of
patients with carnitine would improve ischaemic
muscle metabolism. Carnitine, and an acyl form of
carnitine (proplonyl-l-camitine), are drugs that have
been shown to increase exercise performance and
improve claudication symptoms in small phase II tri-
als.38,39 Larger phase II trials have also shown benefit
of propionyl-L-camitine, with the optimal dose of 2
g/d,32,33(Table 16). Three multicentre, phase III trials
are evaluating the efficacy and safety of propionyl-L-
carnitine in the treatment of claudication."
Prostaglnndin»
Prostaglandins have been used in several studies in
patients with CLl, with some success. In one open-
label study of claudicants, 44 patients were treated
either without an infusion (control group), with intra-
venous pentoxifylline, or with intravenous
prostaglandin E} (PCEl) for 4 weeks." All patients also
underwent an exercise rehabilitation program. The
exercise program alone resulted in a 99% increase in
maximal walking distance; pentoxifylline, a 119%
increase; and PCEl, a 371% increase. Because this trial
was unblinded and not placebo controlled, and
patients had a combined intervention of exercise train-
ing and drug, the results need to be confirmed with
additional studies.
A prodrug of PCEI (AS-013) was studied in a ran-
domised, controlled, prospective study of 80 patients
with IC, comparing placebo with three dosage regi-
mens of the drug given intravenously for 5 days per
week over 8 weeks. There was a significantly greater
increase (p < 0.01) in maximum walking distance in
the combined active treatment group (53%) compared
with the placebo group (-14%). There was also a dose-
related improvement in the response to a quality-of-
life questionnaire.> In another recent study, intra-
venous PCE} given for 5 days per week over 4 weeks
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and twice weekly per week for a further 4 weeks was
compared with placebo in 213 claudicants, At the end
of the 8 weeks of treatment, pain-free walking distance
increased by 60% in the placebo group compared with
101% in the treated group (p < 0.05). These improve-
ments remained virtually unchanged over 3 months'
follow-up without treatment.v
Intravenous administration may not be the most
practical preparation. The recent development of an
oral preparation may be more suitable in patients with
Ie. The experience with orally active prostaglandins in
claudication is more limited, with only two published
reports for evaluation. Beraprost is a PCh analog that is
orally active. A single phase II dose-ranging study has
been published in which 164 patients were randomised
to placebo or three doses of drug.'?The improvement in
absolute claudication distance over placebo was as fol-
lows: 60 ~lg/d produced a 48% increase, 120 ~lg/d a
51% increase, and 180 ~lg/d a 31% increase (Table 16).
None of these changes was statistically significant. A
concern was that at the highest dose, 62% of the
patients reported side effects of headache, flushing, and
gastrointestinal intolerance. Several phase III trials are
evaluating the effectivenes s of these drugs in claudica-
tion, and it is hoped that these studies will clarify the
utility of this class of drug.
Critical Issue 8: Use of prostanoids for symptoms of
intermittent claudication
There is a need to investigate the possibly greater
efficacy of prostanoids in patients with intermittent
claudication, because most randornised, open, or
double-blind trials with intraarterial or intravenous
prostanoids have been performed in patients with
end-stage critical limb ischaemia. Predictors to
select the most suitable patients for prostanoid
treatment need to be determined.
Yascuiar endothelial grototlt [actor
Vascular endothelial growth factor (VECF) and basic
fibroblast growth factor (bFCF) are mitogenic agents
for the development of new collateral channels in
models of peripheral ischaemia. VECF has been
shown to augment collateral vessel development and
increase capillary density in skeletal muscle in a rabbit
model." This effect has been observed when the VECF
protein is administered by intraarterial infusion and
when the DNA encoding for VECF is given by intra-
muscular injection.v Early phase I and phase II trials
are now in progress to determine whether this novel
therapy has a clinical application in patients with clau-
dication and severe leg ischaemia.
Other /lew agents
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L-arginine is an amino acid that has been shown to
improve nitric oxide formation and endothelial-
dependent vasodilatation in patients with atheroscle-
rosis. A few small studies have been performed with
this compound in patients with claudication.w" These
studies have shown improvements in pain-free and
maximal walking distance, but larger studies are nec-
essary to determine the benefit of this treatment.
Another new class of agent is drugs that open potassi-
um channels in vascular smooth muscle. In animal
studies, this unique vasodilating drug improves mus-
cle blood flow and energy metabolism in experimental
models of vascular disease." Other metabolic factors
that may be addressed in PAD include modification of
the balance between fatty acids versus carbohydrates
as substrates for ischemic skeletal muscle. Although
fatty acids are a plentiful source of energy, they
require relatively more oxygen than carbohydrates for
complete oxidation. The adenosine triphosphate
(ATP)/oxygen ratio is 5.7 for fatty acids and 6.3 for
glucose. Thus, when oxygen is limited, as during
claudication, a shift toward carbohydrate metabolism
would be favourable in terms of ATP production.
Several agents are now under investigation that
address these concepts.
B 4.2.5
Summary: Pharmacotherapy for Symptoms of
Intermittent Claudication
In summary, patients with Ie have cardiovascular risk
factors that are critical to identify and modify to
decrease the mortality risk of coronary and cere-
brovascular disease. The pharmacological treatment
of claudication itself is limited to a few drugs of uncer-
tain efficacy. However, several new drugs are under
investigation and may show marked benefit in the
direct treatment of claudication symptoms.
Critical Issue 9: New pharmacological agents for
~toms of intermittent claudication
There is a need for extensive clinical trials to iden-
tify the place, if any, of emerging pharmacological
agents in the treatment of symptoms of intermittent
claudication. Such pharmacological agents may fiII
the need for an additional effective therapy besides
exercise training and intervention.
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B 4.3
Endovascular Procedures for Intermittent
Claudication
B 4.3.1
General Concepts Regarding Catheter Intervention in
PAD
Intervention by endovascular procedure or surgery is
only indicated in selected patients with IC in whom
exercise treatment has failed. Imaging-guided catheter
intervention for PAD was first described by Dotter
and Judkins! in 1964. Since that original report of PTA
in femoropopliteal arteries using coaxial catheter tech-
niques, more than 30 years have passed. The materials
and methods have now been refined, practitioners
have been and continue to be trained, and the applica-
tion of percutaneous transluminal balloon angioplasty
(PTA) and now stenting in PAD has become more
widespread.
Endovascular interventions other than balloon and
stcnt procedures may have a limited application in
selected patients and are therefore not emphasised
here. The following section considers the role of PTA
and stenting in PAD patients with IC and aortoiliac
disease, femoropopliteal disease, or both. Most trials
cited were on claudicants only. Thrombolytic therapy
has a role in some new claudicants and in previously
stable claudicants whose symptoms worsen because
of thrombosis superimposed on atherosclerotic steno-
sis (particularly those with thrombus-dominant rather
